Archives

Choose a date range

From To

Choose one or more categories

Categories:



 


ABPI establishes Inward Investor Group

Wednesday, July 23, 2014 10:45 AM

The Association of the British Pharmaceutical Industry (ABPI) has established a new Inward Investor Group to demonstrate the importance of inward investment to the U.K. and the global mobility of such investment. The group also will work toward cultivating a favorable environment for pharmaceutical companies to invest in the U.K.

More... »

WIRB Copernicus Group

Cipla to expand global footprint, investing in U.K. subsidiary

Wednesday, July 23, 2014 10:42 AM

India-based Cipla has announced a collaboration with the U.K. government to invest up to $170 million in its U.K. subsidiary over the next few years.

More... »

CRF Health eCOA webinar series

Changes in generic pill color and shape disrupt use

Wednesday, July 23, 2014 10:38 AM

Studying a national cohort of patients who recently suffered a heart attack, researchers from Brigham and Women’s Hospital (BWH) have found variation in appearance of generic drugs is associated with a greater risk of patients stopping their essential post-heart attack drugs.

More... »

Seven pharma companies offer deprioritized compounds for re-purposing

Wednesday, July 23, 2014 10:15 AM

U.K. researchers will be granted access to a ‘virtual library’ of deprioritized pharmaceutical compounds through a new partnership between the Medical Research Council (MRC) and seven global drug companies.

More... »

Butrans Transdermal System CIII receives FDA approval for new dosage strength

Wednesday, July 23, 2014 08:00 AM

Purdue Pharma has announced that the FDA approved a new 7.5mcg/hour dosage strength of Butrans (buprenorphine) Transdermal System CIII. Five strengths of Butrans now will be available: 5mcg/hour, 7.5mcg/hour, 10mcg/hour, 15mcg/hour and 20mcg/hour. The Butrans Transdermal System also is approved to allow the use of two patches to facilitate dose adjustments during titration. The total dose from both patches should not exceed 20mcg/hour. Purdue expects to launch Butrans 7.5mcg/hour commercially in the U.S. in October 2014.

More... »

David Hall joins Rho as principal investigator of bioinformatics

Wednesday, July 23, 2014 08:00 AM

Rho, a privately held CRO focused on bringing new products to market through a full range of product development services, has announced that David Hall has joined its team as a principal investigator (PI) specializing in bioinformatics at its Research Triangle Park headquarters in North Carolina. David brings more than 12 years of experience in bioinformatics as a principal investigator, general manager, project manager, bioinformatics lead, programmer/analyst, data modeler and software engineer. 

More... »

Aptuit names Paul Overton EVP, business development & marketing

Tuesday, July 22, 2014 08:00 AM

Aptuit, a provider of integrated early to mid-phase drug development services, has appointed Paul D. Overton, Ph.D., executive vice president, business development and marketing, making him responsible for all of Aptuit's sales and marketing activities.

More... »

Ruthigen treats first human subjects in clinical trial for RUT58-60

Tuesday, July 22, 2014 08:00 AM

Ruthigen, a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics designed to prevent and treat infection in invasive applications, has treated the first human subjects with its drug candidate RUT58-60 in a 30 patient, 21-day skin irritation trial, which is expected to be completed in August.

More... »

Allergan to restructure, cutting 1,500 employees

Monday, July 21, 2014 03:35 PM

As a result of a review of its operations and processes, Allergan will execute a restructuring it estimates will deliver annual pre-tax savings of approximately $475 million in calendar year 2015. Allergan will focus resources on the highest value opportunities, streamline its organizational structure, simplify processes and interfaces, optimize site footprints and enhancie strategic sourcing of goods and services.

More... »

Alzheimer's disease market forecast to reach nearly $12B by 2023

Monday, July 21, 2014 03:29 PM

Decision Resources Group has found the market for Alzheimer's disease (AD) therapies will more than triple, reaching nearly $12 billion by 2023, largely due to the forecasted launch of the first disease-modifying therapies (DMTs), a landmark event in AD treatment.

More... »

CenterWatch Drugs in Clinical Trials
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

July 21

As job growth in drug development sector soars, more employees are seeking new opportunities

U.K. study: Prisoners should have the right to participatein clinical trials on moral grounds, for healthcare access

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

CRO market poised for growth and consolidation
Sponsors expanding pipelines, shrinking infrastructure fuel strategic outsourcing

Strategies for success evolving in phase I space
Sites see increasing complexity, more patients, greater focus on efficacy

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs